1294 Results for "

selective binding

" in MedChemExpress (MCE) Product Catalog:
Products (1294)

1294 Results for "selective binding" in MCE Product Catalog:

669
669 Publications Verification
Referencia número: HY-100523
No. CAS: 846557-71-9
Pureza:  99.96%
Áreas de investigación:  

Cardiovascular Disease Cancer

ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma .
loading...
    loading...
434
434 Cited Publications
Referencia número: HY-12028
No. CAS: 167869-21-8
Pureza:  98.89%
Áreas de investigación:  

Cancer

PD98059 is a potent and selective MEK inhibitor with an IC50 of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC50 of 2-7 µM) and MEK2 (IC50 of 50 µM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC50 of 4 μM) and AHR transformation (IC50 of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy .
loading...
    loading...
135
135 Cited Publications
Referencia número: HY-15463
No. CAS: 152459-95-5
Pureza:  99.95%
Synonyms: STI571; CGP-57148B
Áreas de investigación:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
69
69 Cited Publications
Referencia número: HY-14428
No. CAS: 780757-88-2
Pureza:  99.86%
Target:  

β-catenin Apoptosis

Áreas de investigación:  

Cancer

ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
loading...
    loading...
68
68 Cited Publications
Referencia número: HY-16711
No. CAS: 182498-32-4
Target:  

CXCR

Áreas de investigación:  

Inflammation/Immunology Endocrinology Cancer

SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
loading...
    loading...
61
61 Cited Publications
Referencia número: HY-100514
No. CAS: 1652591-81-5
Pureza:  99.48%
GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.
loading...
    loading...
57
57 Cited Publications
Referencia número: HY-13956
No. CAS: 111025-46-8
Pureza:  99.89%
Synonyms: U 72107
Target:  

PPAR Ferroptosis

Áreas de investigación:  

Metabolic Disease Cancer

Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
loading...
    loading...
55
55 Cited Publications
Referencia número: HY-10010
No. CAS: 461054-93-3
Pureza:  99.97%
Target:  

BCRP

Áreas de investigación:  

Cancer

Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .
loading...
    loading...
53
53 Cited Publications
Referencia número: HY-15084B
No. CAS: 77086-21-6
Pureza:  99.90%
Synonyms: MK-801
Target:  

iGluR

Áreas de investigación:  

Neurological Disease

Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
loading...
    loading...
52
52 Cited Publications
Referencia número: HY-103666
No. CAS: 1073612-91-5
Pureza:  99.58%
Áreas de investigación:  

Inflammation/Immunology

CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
loading...
    loading...
48
48 Cited Publications
Referencia número: HY-10074
No. CAS: 507475-17-4
Pureza:  98.60%
Target:  

IKK STAT Apoptosis

Áreas de investigación:  

Inflammation/Immunology Cancer

TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation.
loading...
    loading...
43
43 Cited Publications
Referencia número: HY-12497
No. CAS: 219766-25-3
Pureza:  99.90%
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory .
loading...
    loading...
42
42 Cited Publications
Referencia número: HY-15319
No. CAS: 473719-41-4
Pureza:  99.80%
Target:  

CXCR

Áreas de investigación:  

Inflammation/Immunology Endocrinology Cancer

AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively .
loading...
    loading...
41
41 Cited Publications
Referencia número: HY-100714A
No. CAS: 79055-68-8
Pureza:  99.94%
Synonyms: D-APV; D-2-Amino-5-phosphonovaleric acid
Target:  

iGluR

Áreas de investigación:  

Neurological Disease

D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors .
loading...
    loading...
37
37 Cited Publications
Referencia número: HY-D1913
Fe2Orange is a Fe 2+ selective probe with an excitation wavelength of 543 nm and an emission wavelength of 580 nm. Fe2Orange emits fluorescence after binding to intracellular Fe 2+, thereby achieving specific labeling of Fe 2+. Fe2Orange is used to detect the content and distribution of Fe 2+ in cells .
loading...
    loading...
37
37 Cited Publications
Referencia número: HY-17600
No. CAS: 1420477-60-6
Synonyms: Calquence; ACP-196
Target:  

Btk

Áreas de investigación:  

Infection Inflammation/Immunology Cancer

Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
35
35 Cited Publications
Referencia número: HY-P0023
No. CAS: 161552-03-0
Target:  

Integrin

Áreas de investigación:  

Cancer

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
35
35 Cited Publications
Referencia número: HY-P0023A
No. CAS: 500577-51-5
Target:  

Integrin

Áreas de investigación:  

Cancer

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
35
35 Cited Publications
Referencia número: HY-138565
No. CAS: 2563855-03-6
Pureza:  99.89%
Target:  

YAP

Áreas de investigación:  

Cancer

K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
loading...
    loading...
33
33 Cited Publications
Referencia número: HY-18730
No. CAS: 180001-34-7
Synonyms: W1400
Target:  

NO Synthase Apoptosis

Áreas de investigación:  

Cardiovascular Disease Inflammation/Immunology Cancer

1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a Kd value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .
loading...
    loading...